NAFDAC Barely 24 hours after the World Health Organisation, WHO, suspended all clinical trials for hydroxychloroquine as a potential treatment for COVID-19, the National Agency for Food and Drug Administration and Control, NAFDAC, has said the trial will continue in Nigeria.
The Director-General of the agency, Mojisola Adeyeye, stated this yesterday in an interview on a private television station. The UN agency had on Monday said it had ‘temporarily’ suspended the clinical trials of hydroxychloroquine as a potential treatment for COVID-19 over safety concerns, adding that the decision followed a study in The Lancet that the use of the drug on COVID-19 patients could increase their likelihood of dying.
“The Executive Group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity Trial while the data is reviewed by the Data Safety Monitoring Board,“ WHO Director-General, Tedros Ghebreyesus had said.
It is a member of an important series of chemically related agents known as quinoline derivatives. Hydroxychloroquine is a related compound that was introduced in 1955. But Mrs Adeyeye said there were proven records that hydroxychloroquine had been effective in the treatment of COVID-19 patients. According to her, this is most effective in those at the mild stage of the virus.
“There is data to prove that hydroxychloroquine worked for many COVID-19 patients. Therefore, we would continue our own clinical trials in Nigeria. Hydroxychloroquine has been proved to work at a mild stage. So the potency depends on the severity of the disease in the patient’s body,” she said.